Collection / PT-141
PT-141
PT-141, also known as bremelanotide, is a melanocortin receptor agonist studied in sexual-response signalling. Its receptor-focused identity offers a neural perspective distinct from reproductive-hormone peptides.
Simulation only · No real order or payment.
Melanocortin receptor agonist
Also known as: Bremelanotide
Official US labelResearch & handling
Not for human or veterinary use. Storage, handling, identity and purity require verified batch documentation. No dosing or treatment advice is provided.
At a glance
Melanocortin receptors
Receptor activity is the starting point for understanding its neural signalling role.
Sexual-response research
Reviewed clinical findings describe a specific manufactured formulation and study population.
Distinct pathway
Its melanocortin identity differs from kisspeptin’s reproductive-axis pathway.
Explore the study context and sources below. For laboratory research only.
Studies & context
Bremelanotide is studied for sexual-desire endpoints in a defined population; receptor activity does not establish a broad performance benefit.
Official US labelThe US indication is narrowly defined for acquired, generalized HSDD in premenopausal women; its mechanism for that indication is not fully known.
Study limitations
The approved formulation is not this research material; US labelling is not Canadian authorization.
The label reports nausea, transient blood-pressure increases and hyperpigmentation among safety considerations.
Study limitations
The indication does not extend to performance enhancement, men or postmenopausal women.
Published research is separate from PEPTIVIA identity, content, purity, sterility and batch documentation. No source-supplier report verifies PEPTIVIA material.